keangkong
GLP-1 Specialist
- Member Since
- Sep 2, 2024
- Posts
- 1,840
- Likes Received
- 4,857
@ZippityDooDah Maybe it's time to create a new category for eloralintide. It's an amylin-based weight loss drug.
Right now, most weight loss drugs are what are referred to as GLP-1 drugs, including drugs that only work on the GLP-1 system and drugs that also work on the glucagon and/or GIP systems.
Here is a study describing a 48 week phase two study on elorantide. It produced a 20% weight loss over the 48 weeks in those who took the maximum dose.
Billings, et al. (pre-publication, 2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity - a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet, doi-10.1016/S0140-6736(25)02155-5, https://1drv.ms/b/c/d63cedb6db1eefc3/Efm5F9RRts5JnrKihcpJoN0B1BE1tSjoKK_VUYjg43vc4Q?e=potceA.
I look forward to seeing other options for people who can't tolerate GLP-1 drugs, those who receive little benefit from them, and those who will need to take additional medication to meet their health goals.
Right now, most weight loss drugs are what are referred to as GLP-1 drugs, including drugs that only work on the GLP-1 system and drugs that also work on the glucagon and/or GIP systems.
Here is a study describing a 48 week phase two study on elorantide. It produced a 20% weight loss over the 48 weeks in those who took the maximum dose.
Billings, et al. (pre-publication, 2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity - a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet, doi-10.1016/S0140-6736(25)02155-5, https://1drv.ms/b/c/d63cedb6db1eefc3/Efm5F9RRts5JnrKihcpJoN0B1BE1tSjoKK_VUYjg43vc4Q?e=potceA.
I look forward to seeing other options for people who can't tolerate GLP-1 drugs, those who receive little benefit from them, and those who will need to take additional medication to meet their health goals.